Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) EBIT : ¥73 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Hubei Hongyuan Pharmaceutical Technology Co EBIT?

Hubei Hongyuan Pharmaceutical Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥73 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hubei Hongyuan Pharmaceutical Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 was 4.17%. Hubei Hongyuan Pharmaceutical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hubei Hongyuan Pharmaceutical Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.63%.

Hubei Hongyuan Pharmaceutical Technology Co EBIT Historical Data

The historical data trend for Hubei Hongyuan Pharmaceutical Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Hongyuan Pharmaceutical Technology Co EBIT Chart

Hubei Hongyuan Pharmaceutical Technology Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

410.85

321.08

547.42

481.39

111.96

Hubei Hongyuan Pharmaceutical Technology Co Quarterly Data
	Jun15	Dec15	Jun16	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															76.60	4.99	42.60	-12.23	37.64

Competitive Comparison of Hubei Hongyuan Pharmaceutical Technology Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Hongyuan Pharmaceutical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hubei Hongyuan Pharmaceutical Technology Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hubei Hongyuan Pharmaceutical Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hubei Hongyuan Pharmaceutical Technology Co's EV-to-EBIT falls into.

Hubei Hongyuan Pharmaceutical Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥73 Mil.

Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hubei Hongyuan Pharmaceutical Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	140.548 * ( 1 - 11.06% )	/	( (3058.557	+	2930.771)	/ 2 )
=	125.0033912	/	2994.664
=	4.17 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5650.771	-	704.491	-	( 1887.723	-	max(0, 914.828	-	3202.266	+	1887.723	))
=	3058.557

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5640.263	-	687.453	-	( 2022.039	-	max(0, 875.871	-	3080.763	+	2022.039	))
=	2930.771

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hubei Hongyuan Pharmaceutical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	150.544	/	( ( (1909.965 + max(-67.515, 0))	+	(1972.371 + max(-308.188, 0)) )	/	2 )
=	150.544	/	( ( 1909.965	+	1972.371 )	/	2 )
=	150.544	/	1941.168
=	7.76 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(210.574	+	191.506	+	378.734)	-	(704.491	+	0	+	143.838)
=	-67.515

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(205.914	+	225.12	+	71.095)	-	(687.453	+	0	+	122.864)
=	-308.188

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hubei Hongyuan Pharmaceutical Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	72.993	/	4480.547
	=	1.63 %

Hubei Hongyuan Pharmaceutical Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Hubei Hongyuan Pharmaceutical Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hubei Hongyuan Pharmaceutical Technology Co Ltd (SZSE:301246) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

No. 8, Hongyuan Road, Economic Development Zone, Luotian County, Hubei Province, Fengshan Town, CHN, 438600

Website

http://www.hbhypharm.com

Hubei Hongyuan Pharmaceutical Technology Co Ltd is engaged in the research and development, production and sales of organic chemical raw materials, pharmaceutical intermediates, raw materials and pharmaceutical preparations.

Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Headlines

No Headlines